Stewart, A K <br/><br/>
Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Sep 2001 
 - 3771-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0732-183X 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2001.19.17.3771  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antigens, CD34--analysis<br/>Antineoplastic Agents--therapeutic use<br/>Bone Marrow Purging--methods<br/>Combined Modality Therapy<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Multiple Myeloma--immunology<br/>Neoplastic Cells, Circulating--immunology<br/>Polymerase Chain Reaction<br/>Proportional Hazards Models<br/>Survival Rate